Evidence map›Paper›PMID 39565472›Full record

ReviewCell biology and toxicology2024

Advancing gastric cancer treatment: nanotechnology innovations and future prospects.

Tengfei Yang, Lin Guo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell biology and toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Polymer Nanoparticles Advancements for Gynecological Cancers.International journal of nanomedicine · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tengfei YangDepartment of Health Management, Shengjing Hospital of China Medical University, Shenyang, 110004, P. R. China.
Lin GuoDepartment of General Surgery, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning Province, P. R. China. guolin@sj-hospital.org.

Funding

a grant from the Key Project of Science and Technology Committee of Shenyang Province No. 202301235SY
6 · The paper itself

Abstract

Gastric cancer (GC) is the fifth most common cancer worldwide, particularly prevalent in Asia, especially in China, where both its incidence and mortality rates are significantly high. Meanwhile, nanotechnology has demonstrated great potential in the treatment of GC. In particular, nanodrug delivery systems have improved therapeutic efficacy and targeting through various functional modifications, such as targeting peptides, tumor microenvironment responsiveness, and instrument-based methods. For instance, silica (SiO

Indexed as

Drug Delivery SystemsNanotechnologyStomach NeoplasmsAnimalsAntineoplastic AgentsDrug CarriersHumansNanoparticlesTumor MicroenvironmentAntineoplastic AgentsDrug CarriersDrug deliveryGCHER2 receptorsIntegrinsNanotechnologyTumor microenvironment

Identifiers

PMID39565472
PMCPMC11579161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.